|
EFNB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.78845827036866E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.9279690611238E-13 |
| Normal-vs-Stage2 |
2.08329999999979E-05 |
| Normal-vs-Stage3 |
1.05969999997235E-06 |
| Normal-vs-Stage4 |
5.275600E-03 |
| Stage1-vs-Stage2 |
6.794400E-01 |
| Stage1-vs-Stage3 |
2.046400E-01 |
| Stage1-vs-Stage4 |
1.142760E-01 |
| Stage2-vs-Stage3 |
5.920000E-01 |
| Stage2-vs-Stage4 |
3.114200E-01 |
| Stage3-vs-Stage4 |
5.192600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.92064158916128E-12 |
| Normal-vs-AfricanAmerican |
8.637300E-04 |
| Normal-vs-Asian |
1.243280E-03 |
| Caucasian-vs-AfricanAmerican |
8.361400E-01 |
| Caucasian-vs-Asian |
7.833000E-01 |
| AfricanAmerican-vs-Asian |
7.323400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.67860003253662E-09 |
| Normal-vs-Female |
1.0538236949742E-12 |
| Male-vs-Female |
7.960000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.71973587884622E-12 |
| Normal-vs-Age(41-60Yrs) |
1.16889997681113E-09 |
| Normal-vs-Age(61-80Yrs) |
3.65860000000051E-05 |
| Normal-vs-Age(81-100Yrs) |
7.392400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.624830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.811600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.154400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.177000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.357400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.594400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.426200E-02 |
| Classical-VS-Follicular |
6.298200E-02 |
| Classical-VS-Other |
3.078800E-01 |
| Classical-VS-Normal |
1.63524749297039E-12 |
| Tall-VS-Follicular |
3.229000E-01 |
| Tall-VS-Other |
9.368800E-01 |
| Tall-VS-Normal |
3.343600E-02 |
| Follicular-VS-Other |
5.241000E-01 |
| Follicular-VS-Normal |
7.05639999987184E-07 |
| Other-VS-Normal |
4.335600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.02009997618546E-09 |
| Normal-vs-N1 |
1.178640E-03 |
| N0-vs-N1 |
9.116000E-01 |
|
|
